Drugs / AZD5396
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05293249 | May 2022 → Jun 2025 | — | Pablo Tebas | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5396 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05293249 ↗ |
| Known as | dMAb AZD5396 | “Participants will receive one injection of dMAb AZD5396 with Hylenex into the arm (deltoid)/leg (quadriceps) region followed by EP.” NCT05293249 ↗ |